[
    {
        "Sponsor": "TP Therapeutics",
        "NCT #": "NCT03093116",
        "Protocol Title": "A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "PREMIA",
        "NCT #": "NCT03012776",
        "Protocol Title": "A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPSTM System \u00a0",
        "Principal Investigator": "Jared Ament, MD"
    },
    {
        "Sponsor": "ImmunityBio",
        "NCT #": "NCT03520686",
        "Protocol Title": "A Phase 2, Open-Label, Randomize Stuy of ALT-803, A Fusion Protein Activator of Natural Killer and T Cells, in Combination with Pembrolizumab vs Pmbrolizumab Alone as First-Line Treatment for Patient with Metastatic Non-Small Cell Lung Cancer (NSCLC)",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "Doterra",
        "NCT #": "NCT05218044",
        "Protocol Title": "Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ",
        "Principal Investigator": "Dennis Holmes, MD"
    },
    {
        "Sponsor": "Pfizer",
        "NCT #": "NCT04821622",
        "Protocol Title": "TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "Pfizer",
        "NCT #": "NCT03395197",
        "Protocol Title": "A Phase 3, Randomized, Double\u2011Blind, Placebo\u2011Controlled Study of Talazoparib WITH ENZALUTAMIDE in Metastatic Castration\u2011Resistant Prostate Cancer TALAPRO2",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "RADIUS",
        "NCT #": "NCT03778931",
        "Protocol Title": "Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients with ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Controlled, Multicenter Trial (EMERALD)",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "ABIOMED ",
        "NCT #": "NCT04763200",
        "Protocol Title": "Impella\u00ae-Supported PCI in High-Risk Patients with Complex Coronary Artery Disease and Reduced Left Ventricular Function: The PROTECT IV Trial",
        "Principal Investigator": "Hambik Tankazyan, DO"
    },
    {
        "Sponsor": "Caris Life Sciences",
        "NCT #": "NCT05692466",
        "Protocol Title": "DINOSAur: Discovering novel cancer treatment options using a comprehensive NGS-based molecular testing panel in the community setting",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "ABIOMED",
        "NCT #": "NCT05334784",
        "Protocol Title": "Use of the Impella ECP\u2122 in Patients Undergoing an Elective or Urgent High-Risk Percutaneous Coronary Intervention",
        "Principal Investigator": "Hambik Tankazyan, DO"
    },
    {
        "Sponsor": "AHGL Office of Integrated Research",
        "NCT #": "NCT05703243",
        "Protocol Title": "Discovering novel cancer treatment options using a comprehensive NGS-based liquid molecular testing panel in the community setting. (\u201cDINOSAur II\u201d)",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "Novartis",
        "NCT #": "NCT05147220",
        "Protocol Title": "A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib",
        "Principal Investigator": "Artin Minaeian, MD"
    },
    {
        "Sponsor": "Janssen",
        "NCT #": "NCT05702034",
        "Protocol Title": "\u201cA Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack LIBREXIA-STROKE\u201d",
        "Principal Investigator": "Lance Lee, MD"
    },
    {
        "Sponsor": "Dilon Technologies",
        "NCT #": "NCT05377229",
        "Protocol Title": "MarginProbe\u00ae 2.0 Data Collection Study  ",
        "Principal Investigator": "Dennis Holmes, MD"
    },
    {
        "Sponsor": "Stemline Therapeutics",
        "NCT #": "NCT05563220",
        "Protocol Title": "Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacastrant in Various Combination In Patients with Metastatic Breast Cancer (ELEVATE)",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "Philips",
        "NCT #": "NCT04451044",
        "Protocol Title": "Multi-center, prospective, randomized controlled study comparing PCI guided by angiography versus iFR Co-Registration using commercially available Philips pressure guidewires and the SyncVision co-registration system, employing an adaptive design study for interim sample size re-estimation.",
        "Principal Investigator": "Hambik Tankazyan, DO"
    },
    {
        "Sponsor": "University of Pittsburg",
        "NCT #": "In process",
        "Protocol Title": "Combined Thrombectomy for Distal MediUm Vessel Occlusion StroKe (DUSK)",
        "Principal Investigator": "Mikayel Grigoryan, MD"
    },
    {
        "Sponsor": "Prostate Conditions Education Council (PCEC)",
        "NCT #": "NA--Screening study",
        "Protocol Title": "Prostate   Cancer   Awareness Screening    ",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "DiaMedica",
        "NCT #": "NCT05065216",
        "Protocol Title": "Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)",
        "Principal Investigator": "Lance Lee, MD"
    },
    {
        "Sponsor": "xCures Vaccine study",
        "NCT #": "NA--Expanded Access Study",
        "Protocol Title": "\"Expanded access to neoantigen synthetic long peptide vaccine in an indivicual patient with advanced malignancy\"",
        "Principal Investigator": "Mihran Shirinian, MD"
    }
]
